Ann: Trading Halt, page-273

First 273 Last

Share
Profile

Follow
Hock87

155 Posts.

14

21/01/21

21:45

Post #: 50356324
Share

Originally posted by hades86: ↑

You're talking about how the risk is brought up but happily ignoring the downplaying and vitriol that was aimed at everyone who referenced it to the point of death threats. PL literally said he doesn't want to hear it and sees it as a threat to his investment today.

You keep bringing up that figure but once again are refusing to look at the other side of the coin because it doesn't suit your narrative. The revenue is meaningless without a clear idea of operational costs. That is basic bookkeeping. Sure $8m sounds nice but there's a reason the price went to the 9's and immediately regressed to 7's once people digested what was there. It was because about 70% of the subscriber fees were from the annual subs the Crowd1'ers (where did the rest of their 12m go?) pumped into it at launch while the rest were on a monthly or quarterly model.

Translation is that 70% of that 8m will evaporate next quarter.

Now we move to how much of that $8m they'll be entitled to: the reason? Taxes, ongoing costs, and related fees will undoubtedly change this $8m figure and then once all adjustments are made and the net revenue is determined then EM1 will pocket a portion. Will these be ongoing costs that will be repeated even if revenue for the next quarter drops by up to 70% because there won't be as many annual subscribers? Will costs go up as the rollout is "expanded" meaning a bigger chunk for Crowd1 to garnish?

We don't know. Those are material and very realistic concerns which will start adding up each 4C and all of a sudden that $8m seems very vulnerable with all of this lurking over it. And this is why the $8m announcement was a short lived bubble that barely made it to a week.

And this goes back to one of my previous posts: do you think the rest of the market are morons for considering this and other reasons for taking the $8m announcement with a grain of salt? Do you think the rampers here are the only ones that can see the long term rockets here and the evil downrampers really do have an agenda?

Apparently "$8m 120k block the noise count the money" is more aesthetically appealing to you and others.

Expand

if you don’t hold and have a sell sentiment why do you give a f$ck?

EM1 Price at posting: 7.3¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

OJC

SPC to merge with Original Juice Co and Nature One Dairy

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 33 more messages in this thread...

First 273 Last

Add SP8 (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $7.479M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	2403999	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	749507	3

View Market Depth

No.	Vol.	Price($)
5	2403999	0.006
4	1026833	0.005
4	9300000	0.004
3	2300000	0.003
1	1200000	0.002

Price($)	Vol.	No.
0.007	749507	3
0.008	2833808	5
0.009	14606480	6
0.010	18193194	6
0.011	3000000	2

Last trade - 16.35pm 02/10/2024 (20 minute delay)

SP8 (ASX) Chart

Day chart unavailable

Ann: Trading Halt, page-273

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-273

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News